# Mesalazine Treatment in IBS (The MIBS Study)

> **NCT01699438** · PHASE2 · COMPLETED · sponsor: **Hans Törnblom** · enrollment: 211 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Mesalazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01699438
- **Lead sponsor:** Hans Törnblom
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2016-12
- **Final completion:** 2017-02
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2017-02-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01699438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01699438, "Mesalazine Treatment in IBS (The MIBS Study)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT01699438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*